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Abstract
Bacteriophages or phages are bacterial viruses that are known to invade bacterial 
cells and, in the case of the lytic phages, impair bacterial metabolism, causing them 
to lyse. Since the discovery of these microorganisms by Felix d’Herelle, a French-
Canadian microbiologist who worked at Institut Pasteur in Paris, Bacteriophages 
begin to be used in the treatment of human diseases, like dysentery and staphylo-
coccal skin disease. However, due to the controversial efficacy of phage prepara-
tions, and with the advent of antibiotics, commercial production of therapeutic 
phage preparations ceased in most of the Western world. Nevertheless, phages 
continued to be used as therapeutic agents (together with or instead of antibiotics) 
in Eastern Europe and in the former Soviet Union. Therefore, there is a sufficient 
body of data that incite the accomplishment of further studies in the field of phage 
therapy.
Keywords: Bacteriophages, therapy, antimicrobial, viruses, phages
1. Introduction
The resistance of pathogenic bacteria to most, if not all, currently available 
antimicrobial agents, has become a major problem in modern medicine, especially 
because of the increased numbers of immunosuppressed patients. The concern that 
humankind is approaching the “preantibiotics” era is becoming realer day by day, 
and this scenario increases the demand for the development of new antibiotics that 
can be used to treat these life-threatening diseases to human life [1].
Before the discovery and the wide spread use of antibiotics, it was suggested that 
bacterial infections could be prevented and/or treated with the administration of 
bacteriophages. Despite the fact that the clinical studies with bacteriophages were 
discontinued in United States and Western Europe, phages continued to be utilized 
in the former Soviet Union and in Eastern Europe. The results of the studies were 
extensively published in non-English journals, and, therefore, were not available to 
the western scientific community [1]. In this book chapter, we describe the history 
of bacteriophage discovery, the first clinical studies with phages, the application of 
phages in different bacterial diseases, the reason why its usage failed to prevail in 
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the Western World, and last, but not less important, the future prospects of the use 
of Bacteriophages as therapeutical agents in bacterial diseases.
1.1 The discovery of bacteriophages and the first phage therapy research
Bacteriophages or phages are bacterial viruses that are known to invade bacterial 
cells and, in the case of lytic phages, impair bacterial metabolism, causing them to 
lyse. Since the discovery of bacteriophages, there has been a debate over claims for 
who really first discovered these microrganisms. Ernest Hankin, a British bacteriolo-
gist, reported in 1896 an antimicrobial activity against Vibrio cholerae in samples 
of water of Ganges and Jumna rivers in India, and he suggested that this phenom-
enon could be possible by the presence of an unidentified substance that passed 
through the fine porcelain filters and was heat labile, limiting the spread of cholera 
 epidemics [2].
Two years later, the Russian bacteriologist Gamaleya observed a similar phe-
nomenon while working with another bacterial species: Bacillus subtilis [3]. Other 
scientists also observed this event, but with other bacteria. However, none of them 
further explored their findings until Frederick Twort, a medically trained bacte-
riologist from England, reintroduced the subject almost 20 years after Hankin’s 
observation by reporting a similar phenomenon and hypothesizing that it may have 
been due to, among other possibilities, a virus [4]. However, Twort did not continue 
his research because of many reasons, including financial difficulties [4–6] and 
only two years later, bacteriophages were “officially” discovered by Felix d’Herelle, a 
French-Canadian microbiologist at the Institut Pasteur in Paris [1].
Unlike Hankin and Twort, d’Herelle had almost no doubt about the nature of 
the observed phenomenon, and he proposed that it was caused by a virus capable 
of parasitizing bacteria. He and his wife Marie, on 18 October 1916, then decided 
to name this microorganism as “bacteriophage” [5]. The name derived from the 
words “bacteria” and “phagein” (to eat or devour, in Greek), implying that phages 
“eat” or “devour” bacteria. D’Herelle considered himself to be the discoverer of 
bacteriophages, but he acknowledged that his discovery was different from Twort’s 
discovery. Also, in contrast to Twort, d’Herelle carried on studies of bacteriophages 
and strongly supported the idea that phages were live viruses – and not “enzymes” 
as many of his fellow researchers thought. The fight for the priority ceased eventu-
ally and many scientists accepted the independent discovery of bacteriophages, 
naming it as the “Twort-d’Herelle phenomenon” and later, the “bacteriophage 
phenomenon” [1].
2. First studies of phage therapy
After his discovery, d’Herelle used phage to treat dysentery, representing 
the first attempt to use bacteriophages to treat a bacterial disease. The study 
was conducted at the Hospital des Enfants-Malades in Paris in 1919 [5] under 
the supervision of Professor Victor-Henri Hutinel, the Hospital’s Chief of 
Pediatrics. The phage preparation was ingested by d’Herelle, Hutinel and sev-
eral hospital interns in order to test its safety before its usage by humans, more 
specifically, a 12-year-old-boy with severe dysentery. The patient’s symptoms 
disappeared after a single administration of d’Herelle’s antidysentery phage, 
and the boy fully recovered after a few days. The phage preparation proved 
its “efficacy” shortly after, when three other patients presenting bacterial 
dysentery that were treated with one dose of the preparation recovered within 
24 hours of treatment [1].
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However, the results of these studies were not published and the first reported 
application of phages used in the treatment of bacterial diseases happened only 
in 1921 in a study performed by Richard Bruynoghe and Joseph Maisin [7], who 
used bacteriophages to treat staphylococcal skin disease. The bacteriophages were 
injected into and around surgically opened lesions and it was observed a regres-
sion of the infections within 24 to 48 hours. In view of these promising results, 
several companies began commercial production of phages against various bacterial 
pathogens [1].
2.1 Marketing of phages
D’Herelle’s commercial laboratory in Paris produced five phage preparations 
against various bacterial infections: Bacte-coli-phage, Bacte-rhinophage, Bacte-
intesti-phage, Bacte-pyo-phage, Bacte-staphy-phage, and they were marketed by 
what later would become the large French company L’Oreal [5]. The production of 
therapeutic phages also began in the United States at that time. In the 1940s, the Eli 
Lilly Company (Indianopolis, Ind.) produced seven phages for human use against 
staphylococci, streptococci, Escherichia coli, and other bacterial pathogens, which 
consisted of phage-lysed, bacteriologically sterile broth cultures of the targeted 
bacteria (e.g., Colo-lysate, Ento-lysate, Neiso-lysate, and Staphylo-lysate) and 
the same preparations in a water-soluble jelly base (e.g., Colo-iel, Ento-iel, and 
Staphylo-jel). They were used to treat various infections, including abscesses, sup-
purating wounds, vaginitis, acute and chronic infections of the upper respiratory 
tract and mastoid infections. However, due to its controversial efficacy, and with 
the advent of antibiotics, commercial production of therapeutic phages ended in 
most of the Western World [8, 9]. Even so, phages continued to be used therapeuti-
cally (together with or instead of antibiotics) in Eastern Europe and in the former 
Soviet Union.
The institute, during its best times, employed approximately 1,200 researchers 
and support personnel, resulting in a production of phages of several tons a day, 
against a dozen bacterial pathogens, including Staphylococci, Pseudomonas, Proteus, 
and many enteric pathogens [1].
The bacteriophage laboratory of the Institute then began to produce phages for 
the treatment of many diseases, such as septicemia, furunculosis, and pulmonary 
and urinary tract infections and for the prophylaxis or treatment of postoperative 
and posttraumatic infections. In most of the cases, the phages were used against 
multi-drug resistant bacteria that were refractory to the conventional treatment 
with the majority of the antibiotics used in the clinical setting [10–16].
2.2 Experimental studies in animals
The first experimental studies that utilized animals in laboratories on the 
treatment of bacterial diseases using bacteriophages came from the Laboratory of 
William Smith and Smith and his colleagues [17–20] at the Institute for Animal 
Disease Research in Houghton, Cambrigeshire, Great Britain. In one of their first 
published papers, the authors reported the successful use of phages to treat E. coli in 
vitro infections in mice. In the next studies, [18–20] the authors found that a single 
dose of specific E coli phage reduced, by many orders of magnitude, the number 
of targeted bacteria in the digestive tract of calves, lambs, and piglets previously 
infected with a strain of E. coli that caused diarrhea. The treatment also ceased the 
associated fluid loss, and all the animals that were treated with the bacteriophages 
survived the bacterial infection. Furthermore, such positive results rekindled the 
interest in phage therapy in the West World and stimulated other researchers to 
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investigate the possibility of using phages on the treatment of bacterial diseases 
caused by antibiotic resistant bacteria capable of causing human infections.
Another in vivo study performed by Soothill et al. [21] reported the importance 
of the phages in preventing and treating diseases induced experimentally in mice 
and guinea pigs infected with Pseudomonas aeruginosa and Acinetobacter, suggesting 
that its usage might be efficacious in preventing infections of skin grafts used to 
treat burn patients. However, it is uncertain if these “preclinical” studies preceded 
human clinical trials. Indeed, although many human trials were preceded by at least 
some in vitro studies using laboratory animals, the scientific literature regarding 
this topic is scarce.
Since the history of the discovery of the bacteriophages and some pioneer 
studies regarding this subject was already explored, the next section of this book 
chapter will explore the lytic and lysogenic cycles of phages, mode of action of these 
microrganisms when used in the therapy to treat bacterial diseases as well as some 
specific advantages and disadvantages in such use in the clinical settings.
2.3 Lytic and lysogenic life cycles of phages
Recent publications have provided interesting evidence that questions the 
notion that viruses are non-living organisms [22]. Erez et al., in their recent 
publication, identified a communication between viruses. They found a unique 
small-molecule communication system that controls lysis-lysogeny life cycles in 
a temperate phage [23]. Another study described the assembly of a nucleus-like 
structure during the viral replication of phage 201Φ2–1 in Pseudomonas chlorora-
phis, which suggested that phages have evolved a specialized structure to compart-
mentalize viral replication [24].
Phages can go through two different life cycles: the lytic and the lysogenic cycle. 
First, phages bind to the bacterial host specifically on a receptor found on the 
bacteria’s surface and then injects its genetic material into the cell. The phage then 
takes advantage of the bacterium’s biochemical machinery and replicate its genetic 
material, producing progeny phage. Subsequently, the phage synthesizes proteins 
such as endolysin and holin, which lyse the host cell from within. Holins are small 
proteins that accumulate in the cytoplasmic membrane of the host, allowing endo-
lysin to degrade peptidoglycan and the progeny phage to escape the bacterial host. 
In the external environment, lytic phage can infect and destroy all bacteria nearby 
its initial bacterial host (Figure 1). The rapid proliferation and the large number of 
lytic phages are advantageous when they have therapeutic purposes. However, lytic 
phages have narrow host ranges and infect only specific bacterial species. Though, 
it can be overcame by giving a cocktail of different phages to patients afflicted by 
bacterial infections [25].
In the lysogenic cycle, the temperate phages do not immediately lyse the host 
cell, instead, they insert their genome into the bacterial chromosome at specific 
sites. This phage DNA now inserted into the host genome is called prophage, while 
the host cell containing the prophage is called a lysogen. The prophage then repli-
cates along with the bacterial genome, establishing a stable relationship between 
them. The disadvantage of using temperate phage in phage therapy is that once the 
phage DNA is inserted into the bacterial genome, it can remain dormant or even 
alter the phenotype of the host [25].
Another advantage of using temperate phages in phage therapy is that the 
lysogenic cycle can continue indefinitely unless the bacteria are exposed to stress or 
adverse conditions. The signals that triggers such event vary from phage to phage, 
but prophage are commonly induced when bacterial stress responses are activated 
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due to antibiotic treatment, oxidative stress, or DNA damage [26]. Once the 
lysogenic cycle finishes, expression of phage DNA starts and lytic cycle begins. In 
recent studies, it was found that phages that infect Bacillus species depends on small 
molecules called “arbitrium” to communicate to each other and make lysis-lysogeny 
decisions [23].
The biological implication of this phenomenon is very significant and explains 
why when phages encounters a large numbers of bacteria colonies, therefore, find-
ing plenty of hosts to infect, they activate the lytic cycle. If host numbers is limited, 
the progeny phage then activates the lysogenic cycle and enters in a dormancy state. 
These recent findings stimulate other researches to be done to determine if there are 
other peptides also implicated in this phenomenon or if cross-talk is evident among 
different bacteriophage [25].
Furthermore, recent study regarding the full genetic sequence of the T4 
phage (GenBank accession number AF158101) showed that the lysis of the 
bacteria by a lytic phage involves a complex process consisting several structural 
and regulatory genes. Besides, it is also possible that some therapeutic bacterio-
phages have some unique and unidentified genes or mechanisms responsible for 
effectively lysing their targeted bacteria. This led scientists to identify and clone, 
years later, an anti-Salmonella phage possessing a potent lethal activity against 
Salmonella enterica serovar Typhimurium host strains. Another study showed an 
unique mechanism for protecting phage DNA from the restriction-modification 
defenses of an S. aureus host strain. Further studies are necessary to gather 
information that are going to be useful to genetically engineer therapeutic phage 
preparations [27].
Figure 1. 
Diagram representing the lytic and lysogenic cycle of the bacteriophages, as well as their advantages and 
disadvantages on phage therapy.
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2.4 Mode of action of the bacteriophages
The first studies regarding the pharmacokinetics of bacteriophages showed that 
phages got into the bloodstream of laboratory animals after a single oral dose within 
2 to 4 hours and that they were found in the following organs of the human body: 
liver, spleen, kidney, etc. in approximately 10 hours. Additionally, data concerning 
the period of time that the phages can remain in the human body indicate that it can 
happen for a long period of time, i. e., for up to several hours [28].
Despite the efforts in better understanding the pharmacokinetics of phages, 
their self-replication creates a complex scenario influenced by both decrease and 
proliferation. Although in vivo amplification of phages has been already performed, 
the topics are dominated by mathematical models of in vitro infections, which does 
not necessarily corresponds to in vivo amplification [29]. On the other side of it, 
phage lytic enzymes are considered as standard drugs in terms of pharmacokinetics. 
SAL200, a S. aureus-specific endolysin, has a t1/2 between 0.04 and 0.38 hours after 
intravenous administration in healthy volunteers. The authors stated that, based on 
the molecular weight, renal clearance and drug distribution from the intravascular 
to the extravascular space should be minimal. Therefore, the presence of plasma 
proteases can explain the decay of this endolysin [30]. Other endolysins have a 
longer half-life (e.g., CF-302 has a half-life of 11.3 hours, while P128 has a half-life of 
5.2 and 5.6 hours for the highet doses, 30 and 60 mg/kg, respectively) [31, 32]. Thus, 
as lytic enzymes in pre-clinical analyses shows an easier determination of its dosing 
regimen when compared to dosing regimen of phages, lytic enzymes are currently 
preferred to be used on patients [33]. In this sense, further studies are needed to 
better evaluate the pharmacological data concerning the lytic phages, including 
full-scale toxicological researches, before they can be used therapeutically in the 
West World [1].
2.5 Safety in the usage of phage preparations
From a clinical perspective, phages are apparently harmless. During the long 
period of usage of the phages as therapeutic agents in Eastern Europe and in the 
former Soviet Union (and before the antibiotic era, in the United States), phages 
have been administered to humans (i) orally, in tablet or liquid formulations (105 
and 1011 PFU/dose) (ii) rectally (iii), locally (skin, eye, ear, nasal mucosa, etc.), 
in tampons, rinses and creams, (iv) aerosols or intrapleural injections, and (v) via 
intravenous access, though less frequently than the first four cited methods, and 
there are no reports of serious complications associated with their use [1].
Another aspect regarding safety of the bacteriophages usage is that they are 
extremely common in the environment (e. g., nonpolluted water has been reported 
to contain ca. 2x108 bacteriophage per ml) [34] and are usually consumed in 
foods, highlighting their potential to be used as bioremediation agents on polluted 
environments. However, it would be prudent to ensure the safety of these micror-
ganisms before using them as therapeutic agents, making sure, for example that: 
(i) they do not carry out generalized transduction and (ii) have genetic sequences 
possessing considerable homology with some genes related to antibiotic resistance, 
genes for phage-encoded toxins, and genes for other bacterial virulence factors [1].
2.6 Advantages in the use of bacteriophage therapy
Bacteriophage therapy presents many advantages such as high host specificity, 
preventing damage to normal intestinal flora, thus not infecting eukaryotic cells, low 
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dosages required for the treatment, rapid proliferation inside the host bacteria, mak-
ing them ideal candidates to treat bacterial infections [35]. Unlike antibiotics, another 
advantage in the usage of bacteriophages is that they reinfect the bacteria host and 
mutate alongside them [36].
However, high specifity of the phages can be both advantageous and a limiting 
factor. To use a monophage therapy it is necessary to check the efficacy of the 
phage by performing in vitro assays against the disease-causing bacteria before 
applying it in the patient, which can be a laborious task to do. The solution to 
this problem would be to use phage cocktails, which comprises a wide range of 
phages acting against different bacterial species or strains [37]. According to 
experts all around the world, an ideal phage cocktail consists of phages belonging 
to different families or groups so that it would target a broad range of hosts. Also, 
they would have to possess a high absorption ability to the highly conserved cell 
wall structures of the bacterial hosts. Additionally, the usage of phage cocktails 
may reduce the emergence of phage resistant bacterial population. On the other 
side, other researchers defend the sequential use of individual active phages to 
the patient, though, in clinical practice, it appears to be a difficult strategy to 
perform [38].
Not only bacteriophages per se can be used to treat bacterial infections. Their 
by-products can also do the trick. It was already reported that lytic enzymes 
showing function similar to lysozyme can also be used as an antibacterial agent 
or can be used in synergy with other antimicrobials like antibiotics to improve 
the efficacy of the treatment [39]. A phage derived protein, “endolysin”, also 
possesses antibacterial and antibiofilm activity against ESKAPE pathogens 
[39–43]. V12CBD, a recombinant protein derived from bacteriophage lysine, 
PlyV12, was also able to attenuate virulence of S. aureus and also enhance its 
phagocytosis in mice [44].
2.7 Disadvantages in the usage of bacteriophage therapy
It is widely known that phages can be vector for horizontal gene transfer in bacteria, 
and in this process, bacteria can exchange virulence or antibiotic resistance gene, mak-
ing these microrganisms resistant to a wide range of antibiotics [45]. Therefore, phages 
cannot harbor virulence factors or antibiotic resistance genes like integrases, site- 
specific recombinases, and repressor of the lytic cycle that may accelerate the integra-
tion of these genes in the bacterial hosts. Algorithms that can predict the mode of action 
of the phages as well as their virulent traits are available but their database needs to be 
constantly updated with a greater amount of genome sequence of phages [46].
Recent studies demonstrated an in vivo efficacy of phages against infections 
caused by ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella 
pneumoniae, Acinetobacter baumanni, Pseudomonas aeruginosa and Enterobacter 
spp.), and their authors used fully characterized phages that showed no virulence 
factors or antibiotic resistance genes, therefore, they were considered safe as they 
do not provoked any allergic or immune response in the patient, and they were also 
stable at varied pH and temperature, making them ideal candidates for bacterio-
phage therapy [47–50].
Another limitation is the relatively weak stability of phages and their proper 
administration in order to reach the site of action. Phage preparations can be 
applied orally, nasally or topically [51, 52]. To overcome this limitation, studies were 
conducted and they have shown that phage’s efficacy is improved when they are 
entrapped with liposomes [51, 53–55]. They can also reach the infection site in the 
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3. Future perspectives on phage therapy
There is an increasing urge to restock our ammunition of antimicrobials to com-
bat the ever rising drug resistant bacterial pathogens. Effective antibiotic combina-
tions are scarce and to add to the problem, the incoming of new drugs is also very low 
and happens in a very slow pace. Phages are a promising source of new antimicrobial 
drugs and they have been sparking up an interest on researchers all over the world, 
but still, their use is not approved on the United States and in Europe. But once limi-
tations on their use is overcame, like preventing the phages to insert genes on their 
bacterial hosts that could confer them resistance to antibiotics and also the produc-
tion of toxins, for example, the use of bacteriophages to treat bacterial diseases will 
be extremely helpful to treat patients affected by these bacterial diseases.
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